A year after Angelina Jolie went public about her double mastectomy, interest in genetic testing has increased. But a worrying trend is also shaping up: unnecessary breast-removal surgeries.
Since the Supreme Court ruling one year ago, Myriad Genetics is no longer the only lab in the United States conducting BRCA testing. But it refuses to share lifesaving data it has collected.
The stock of Myriad Genetics plunged after the Supreme Court rejected its effort to patent a human gene mutation that is linked to cancer and is common among Ashkenazi Jews.
The Supreme Court ruled unanimously that a private company cannot patent human genes. For Jewish breast cancer advocates, that is cause for celebration — and more work.